Carcinogenesis Advance Access originally published online on July 28, 2005
Carcinogenesis 2005 26(12):2207-2212; doi:10.1093/carcin/bgi191
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis Vol.26 no.12 © Oxford University Press 2005; all rights reserved.
CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study
1 Population Studies and Prevention Program, 2 Department of Internal Medicine, 3 Center for Molecular Medicine and Genetics, 4 Molecular Biology and Human Genetics Program and 5 Proteases and Cancer Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA
* To whom correspondence and reprint requests should be addressed. Tel: +1 313 833 0715 ext. 2484; Fax: +1 313 831 7806; Email: wenzlaff{at}med.wayne.edu
The cytochrome P450 (CYP) superfamily of enzymes catalyse one of the first steps in the metabolism of carcinogens such as polycyclic aromatic hydrocarbons, nitroaromatics and arylamines. Polymorphisms within the CYP1A1 gene have been shown to be associated with lung cancer risk, predominantly among Asian populations. Despite functional evidence of a possible role of CYP1B1 in lung cancer susceptibility, only a few studies have evaluated polymorphisms in this gene in relation to lung cancer susceptibility. This population-based study evaluates polymorphisms in both of these CYP genes within never smokers, most of whom had environmental tobacco smoke (ETS) exposure. Cases (n = 160) were identified through the metropolitan Detroit Surveillance, Epidemiology and End Results program, and age, sex and race-matched population-based controls (n = 181) were identified using random digit dialing. Neither CYP1A1 MspI nor CYP1A1 Ile462Val was associated with lung cancer susceptibility among Caucasians or African-Americans. Among Caucasians, however, CYP1B1 Leu432Val was significantly associated with lung cancer susceptibility odds ratio (OR) for at least one valine allele = 2.87 [95% confidence interval (CI) 1.635.07]. Combinations of this Phase I enzyme polymorphism along with selected Phase II enzyme polymorphisms (GSTM1 null, GSTP1 Ile105Val and NQO1 C609T) were evaluated. The combination of CYP1B1 Leu432Val and NQO1 C609T appeared to be associated with the highest risk of lung cancer (OR = 4.14, 95% CI 1.6010.74), although no combinations differed significantly from the risk associated with CYP1B1 Leu432Val alone. When individuals were stratified by household ETS exposure (yes/no), CYP1B1 Leu432Val alone and in combination with Phase II enzyme polymorphisms was more strongly associated with increased lung cancer susceptibility among those with at least some household ETS exposure. Additional studies will be required to further validate these findings among never smokers and to evaluate the effects of this polymorphism among smoking populations as well.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. Wang, Y. Xiong, Y. Sun, Z. Fang, L. Li, H. Ji, and T. Shi HLungDB: an integrated database of human lung cancer research Nucleic Acids Res., November 9, 2009; (2009) gkp945v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Austin, J. D. Cogan, J. D. West, L. K. Hedges, R. Hamid, E. P. Dawson, L. A. Wheeler, F. F. Parl, J. E. Loyd, and J. A. Phillips III Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females Eur. Respir. J., November 1, 2009; 34(5): 1093 - 1099. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Rudin, E. Avila-Tang, C. C. Harris, J. G. Herman, F. R. Hirsch, W. Pao, A. G. Schwartz, K. H. Vahakangas, and J. M. Samet Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications Clin. Cancer Res., September 15, 2009; 15(18): 5646 - 5661. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Helmig, B. Hadzaad, J. Dohrel, and J. Schneider Influence of the Cyp1B1 L432V Gene Polymorphism and Exposure to Tobacco Smoke on Cyp1B1 mRNA Expression in Human Leukocytes Drug Metab. Dispos., July 1, 2009; 37(7): 1490 - 1495. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Cote, W. Yoo, A. S. Wenzlaff, G. M. Prysak, S. K. Santer, G. B. Claeys, A. L. Van Dyke, S. J. Land, and A. G. Schwartz Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women Carcinogenesis, April 1, 2009; 30(4): 626 - 635. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Aldrich, S. Selvin, H. M. Hansen, L. F. Barcellos, M. R. Wrensch, J. D. Sison, K. T. Kelsey, P. A. Buffler, C. P. Quesenberry Jr., M. F. Seldin, et al. CYP1A1/2 Haplotypes and Lung Cancer and Assessment of Confounding by Population Stratification Cancer Res., March 15, 2009; 69(6): 2340 - 2348. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Castro, W. M. Baird, C. B. Pereira, J. Giovanini, C. V. Lohr, K. A. Fischer, Z. Yu, F. J. Gonzalez, S. K. Krueger, and D. E. Williams Fetal Mouse Cyp1b1 and Transplacental Carcinogenesis from Maternal Exposure to Dibenzo(a,l)pyrene Cancer Prevention Research, July 1, 2008; 1(2): 128 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Carlsten, G. S. Sagoo, A. J. Frodsham, W. Burke, and J. P. T. Higgins Glutathione S-Transferase M1 (GSTM1) Polymorphisms and Lung Cancer: A Literature-based Systematic HuGE Review and Meta-Analysis Am. J. Epidemiol., April 1, 2008; 167(7): 759 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-A. Yoon, S. Park, B. Hwangbo, H. D. Shin, H. S. Cheong, H.-R. Shin, and J. S. Lee Genetic polymorphisms in the Rb-binding zinc finger gene RIZ and the risk of lung cancer Carcinogenesis, September 1, 2007; 28(9): 1971 - 1977. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kury, B. Buecher, S. Robiou-du-Pont, C. Scoul, V. Sebille, H. Colman, C. Le Houerou, T. Le Neel, J. Bourdon, R. Faroux, et al. Combinations of Cytochrome P450 Gene Polymorphisms Enhancing the Risk for Sporadic Colorectal Cancer Related to Red Meat Consumption Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1460 - 1467. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Wakelee, E. T. Chang, S. L. Gomez, T. H. Keegan, D. Feskanich, C. A. Clarke, L. Holmberg, L. C. Yong, L. N. Kolonel, M. K. Gould, et al. Lung Cancer Incidence in Never Smokers J. Clin. Oncol., February 10, 2007; 25(5): 472 - 478. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-A. Yoon, B. Hwangbo, I.-J. Kim, S. Park, H. S. Kim, H. J. Kee, J. E. Lee, Y. K. Jang, J.-G. Park, and J. S. Lee Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer Carcinogenesis, November 1, 2006; 27(11): 2217 - 2222. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Hecht, S. G. Carmella, A. Yoder, M. Chen, Z.-z. Li, C. Le, R. Dayton, J. Jensen, and D. K. Hatsukami Comparison of polymorphisms in genes involved in polycyclic aromatic hydrocarbon metabolism with urinary phenanthrene metabolite ratios in smokers. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1805 - 1811. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-R. Zhu, P. E. Thomas, G. Lu, K. R. Reuhl, G.-Y. Yang, L.-D. Wang, S.-L. Wang, C. S. Yang, X.-Y. He, and J.-Y. Hong CYP2A13 in Human Respiratory Tissues and Lung Cancers: An Immunohistochemical Study with A New Peptide-Specific Antibody Drug Metab. Dispos., October 1, 2006; 34(10): 1672 - 1676. [Abstract] [Full Text] [PDF] |
||||









